search

Active clinical trials for "Neuroectodermal Tumors, Primitive"

Results 101-110 of 142

Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases

Adult RhabdomyosarcomaLung Metastases13 more

This pilot clinical trial studies intensity-modulated radiation therapy (IMRT) in treating younger patients with lung metastases. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

Completed14 enrollment criteria

Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive...

Metastatic MedulloblastomaHigh Risk Supratentorial PNET1 more

The purpose of this study is to study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial PNETs and metastatic PNETs.

Completed8 enrollment criteria

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors...

Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell Tumor19 more

This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Completed45 enrollment criteria

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma,...

Brain and Central Nervous System Tumors

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy in different ways and giving it together with more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which radiation therapy and combination chemotherapy regimen is more effective in treating medulloblastoma, supratentorial primitive neuroectodermal tumor (PNET), or ependymoma. PURPOSE: This clinical trial is studying six different radiation therapy and combination chemotherapy regimens to compare how well they work in treating young patients with medulloblastoma, PNET, or ependymoma.

Completed12 enrollment criteria

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of...

Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorMetastatic Osteosarcoma7 more

This phase II trial is studying how well sorafenib works in treating patients with soft tissue sarcoma. Sorafenib may stop the growth of soft tissue sarcoma by blocking blood flow to the tumor and blocking some of the enzymes needed for tumor cell growth

Completed23 enrollment criteria

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory...

Childhood Acute Promyelocytic Leukemia (M3)Childhood Atypical Teratoid/Rhabdoid Tumor18 more

This phase I trial is studying the side effects and best dose of vorinostat when given together with isotretinoin in treating young patients with recurrent or refractory solid tumors, lymphoma, or leukemia. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Isotretinoin may cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving vorinostat together with isotretinoin may be an effective treatment for cancer.

Completed57 enrollment criteria

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating...

Sarcoma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy, peripheral stem cell transplantation, and radiation therapy in treating patients with recurrent metastatic Ewing's sarcoma, peripheral primitive neuroectodermal tumor, or rhabdomyosarcoma.

Completed3 enrollment criteria

Stereotactic Radiosurgery in Treating Patients With Brain Tumors

Adult Central Nervous System Germ Cell TumorAdult Malignant Meningioma12 more

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of stereotactic radiosurgery in treating patients who have brain tumors.

Completed2 enrollment criteria

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Adult Anaplastic AstrocytomaAdult Anaplastic Ependymoma85 more

Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor

Completed63 enrollment criteria

Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's...

Previously Treated Childhood RhabdomyosarcomaRecurrent Childhood Rhabdomyosarcoma3 more

This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die.

Completed58 enrollment criteria
1...101112...15

Need Help? Contact our team!


We'll reach out to this number within 24 hrs